The DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index.
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Open accessAbstract
Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells. Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents. In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs. This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Spontaneous Human Adult Stem Cell Transformation
Rubio, D., Garcia-Castro, J., Martín, M. C., de la Fuente, R., Cigudosa, J. C., Lloyd, A. C., & Bernad, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4194 · Cited by 1,036
RetractedDeng, J., Yang, M., Jiang, R., An, N., Wang, T., & Liu, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170860 · Cited by 142
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“These include CSC markers (ALDH [203], CD44 [204, 205], CD133 [206], EpCAM [207], and HER2 [208]), CSC niche interaction (TAM [209]), tumor microenvironment (immune cells/myeloidderived suppressor cells), cytokines (IL1 [210], IL6 [211], and IL8 [212]), and immune checkpoint (CTLA-4 [213] or PD1/PDL1 [214]).”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
Chemotherapy: a double-edged sword in cancer treatment
Behranvand, N., Nasri, F., Zolfaghari Emameh, R., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2022) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 397
Gut microbiome and its role in colorectal cancer
Rebersek, M. (2021) · BMC Cancer · doi:10.1186/s12885-021-09054-2 · Cited by 355
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
The nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery
Kwon, Y. W., Jo, H.-S., Bae, S., Seo, Y., Song, P., Song, M., & Yoon, J. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.747333 · Cited by 268
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 260
Natural products: An upcoming therapeutic approach to cancer
Dutta, S., Mahalanobish, S., Saha, S., Ghosh, S., & Sil, P. C. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.012 · Cited by 259
Mechanism of interaction between autophagy and apoptosis in cancer
Das, S., Shukla, N., Singh, S. S., Kushwaha, S., & Shrivastava, R. (2021) · Apoptosis · doi:10.1007/s10495-021-01687-9 · Cited by 255
Roshani, M., Rezaian-Isfahni, A., Lotfalizadeh, M. H., Khassafi, N., Abadi, M. H. J. N., & Nejati, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03115-1 · Cited by 84
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 83
“Their survival and resistance characteristics are reinforced by neighboring non-CSC tumor cells that help maintain a specialized microenvironment or “stem cell niche” [126,127].”
Transcription Factor AP4 Mediates Cell Fate Decisions: To Divide, Age, or Die
Wong, M. M.-K., Joyson, S. M., Hermeking, H., & Chiu, S. K. (2021) · Cancers · doi:10.3390/cancers13040676 · Cited by 36
“Studies have shown that TICs are resistant to various cancer therapies [75] and contribute to cancer relapse after chemo- and radiotherapy [77].”
BackgroundCell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Azarifar, Z., Amini, R., Tanzadehpanah, H., Afshar, S., & Najafi, R. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08888-2 · Cited by 11
Targeted Cancer Stem Cell Therapeutics: An Update
Fatima, N., Umar, M., Ambreen, S., Shaququzzaman, M., Alam, M. M., & Ali, R. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266275014240110071351 · Cited by 6
Metadata
- Authors
- Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y.
- Venue
- Stem Cells International
- Publisher
- Wiley
- Published
- 2018
- Volume
- 2018
- Pages
- 1-16
- ISSN
- 1687-966X (ISSN-L)
- 1687-9678
- OpenAlex
- W2791923388
- Cited by
- 994
- References
- 220
- FWCI
- 28.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.